True North Advisors LLC Sells 42 Shares of Eli Lilly and Company (NYSE:LLY)

True North Advisors LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 1.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,225 shares of the company’s stock after selling 42 shares during the period. Eli Lilly and Company comprises 0.7% of True North Advisors LLC’s investment portfolio, making the stock its 23rd biggest holding. True North Advisors LLC’s holdings in Eli Lilly and Company were worth $2,857,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Capital Planning LLC bought a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in Eli Lilly and Company in the first quarter worth about $6,916,000. M&G Plc purchased a new position in Eli Lilly and Company in the first quarter valued at about $8,896,000. HighPoint Advisor Group LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $9,878,000. Finally, Leo Wealth LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $3,355,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of several research reports. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Truist Financial reiterated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Up 1.7 %

Shares of NYSE:LLY opened at $913.72 on Wednesday. The firm has a market capitalization of $868.40 billion, a P/E ratio of 134.57, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a 50 day moving average price of $904.41 and a 200-day moving average price of $850.31. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.